Almost 60% of clinicians prescribe so-called bioidentical compounded menopausal hormone therapy, against recommendations from major medical societies, according to a new survey.
And 47% of respondents said they disagree with society recommendations that patients should be told that conventional hormone therapy is more appropriate than compounded preparations not approved by the US Food and Drug Administration.
"There is some discrepancy, some disconnect, between the national organizations and clinicians," said Jamie Peregrine-Dubaut, MD, from the University of Kansas School of Medicine in Wichita, who presented the findings here at the American Society for Reproductive Medicine 2015 Annual Meeting
According to a recent survey conducted by the North American Menopause Society (NAMS), 41% of patients are choosing compounded, non-FDA-approved preparations, despite society recommendations against them, as previously reported by Medscape Medical News.
But many physicians say they are comfortable with this practice, according to Dr Peregrine-Dubaut.